We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+18.95%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.85B
AUM Growth
-$38.7M
Cap. Flow
-$602M
Cap. Flow %
-21.14%
Top 10 Hldgs %
27.89%
Holding
132
New
16
Increased
23
Reduced
29
Closed
17

Top Buys

Rank Stock Value
1
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$55.3M
2
XERS icon
Xeris Biopharma Holdings
XERS
+$48.6M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$41.7M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$27.9M
5
TNDM icon
Tandem Diabetes Care
TNDM
+$27.7M

Top Sells

Rank Stock Value
1
AVXS
AveXis, Inc. Common Stock
AVXS
+$93.4M
2
DXCM icon
DexCom
DXCM
+$41M
3
DVA icon
DaVita
DVA
+$32.1M
4
GSK icon
GSK
GSK
+$31.6M
5
VTRS icon
Viatris
VTRS
+$31.6M

Sector Composition

Rank Sector Weight
1 Healthcare 73.94%
2 Financials 2.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
OPCH icon
76
Option Care Health
OPCH
$3.41B
$6.84M 0.24%
583,750
-197,250
-25% -$2.07M
WVE icon
77
Wave Life Sciences
WVE
$1.12B
$6.84M 0.24%
178,806
-89,368
-33% -$3.85M
AUTL
78
Autolus Therapeutics
AUTL
$383M
$6.7M 0.24%
+250,000
New +$6.61M
EIDX
79
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
$6.59M 0.23%
+323,807
New +$6.79M
SLDB icon
80
Solid Biosciences
SLDB
$858M
$6.39M 0.22%
+11,959
New +$3.68M
PFNX
81
DELISTED
Pfenex Inc.
PFNX
$6.11M 0.21%
1,129,684
-529,817
-32% -$3.06M
ALIM
82
DELISTED
Alimera Sciences
ALIM
$5.92M 0.21%
403,529
– –
TECX
83
Tectonic Therapeutic
TECX
$615M
$5.71M 0.2%
+16,667
New +$6.01M
RCKT icon
84
Rocket Pharmaceuticals
RCKT
$376M
$5.5M 0.19%
280,000
-120,000
-30% -$2.27M
SRRA
85
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$5.22M 0.18%
44,122
– –
ALBO
86
DELISTED
Albireo Pharma Inc
ALBO
$4.26M 0.15%
120,000
– –
STDY
87
DELISTED
SteadyMed Ltd
STDY
$4.13M 0.15%
918,120
-500,667
-35% -$2.04M
RARX
88
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.81M 0.13%
382,700
– –
FOMX
89
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$3.38M 0.12%
674,002
– –
STIM icon
90
Neuronetics
STIM
$113M
$3.33M 0.12%
+125,000
New +$3.4M
TARA icon
91
Protara Therapeutics
TARA
$230M
$3M 0.11%
30,622
– –
MNKD icon
92
MannKind Corp
MNKD
$1.25B
$2.77M 0.1%
1,458,537
-24,064
-2% -$45K
NVTR
93
DELISTED
Nuvectra Corporation Common Stock
NVTR
$2.69M 0.09%
+131,000
New +$2.21M
TLGT
94
DELISTED
Teligent, Inc
TLGT
$2.45M 0.09%
70,887
+22,987
+48% +$723K
VYGR icon
95
Voyager Therapeutics
VYGR
$192M
$2.3M 0.08%
117,647
– –
KIDS icon
96
OrthoPediatrics
KIDS
$494M
$2.15M 0.08%
80,783
+22,536
+39% +$481K
HYPD
97
Hyperion DeFi Inc
HYPD
$41.5M
$1.89M 0.07%
3,750
– –
XNCR icon
98
Xencor
XNCR
$1.3B
$1.79M 0.06%
48,366
-834,096
-95% -$28.7M
NEOS
99
DELISTED
Neos Therapeutics, Inc
NEOS
$1.46M 0.05%
233,332
-631,574
-73% -$4.71M
ARLZ
100
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$576K 0.02%
1,644,583
– –
1 2 3
4
5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q2 2018 Portfolio in Review

As of Q2 2018, Deerfield Management held 132 positions worth $2.85B, down 1.3% from $2.89B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

Deerfield Management withdrew a net $602M in Q2 2018, closing 17 positions and reducing 29 holdings. Its most notable exit was AveXis, Inc. Common Stock, an estimated $93.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, down from 75% a quarter earlier, followed by Financials.

Against the trend, Deerfield Management opened a new position in Portola Pharmaceuticals, Inc. worth $54.6M.

  • Deerfield Management's largest Q2 2018 buy was Portola Pharmaceuticals, Inc.: 1,446,633 shares worth $54.6M.
  • Deerfield Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2018, an estimated $41.7M increase.
  • Deerfield Management's biggest Q2 2018 reduction was DexCom, cutting an estimated $41M.
  • Deerfield Management fully exited AveXis, Inc. Common Stock in Q2 2018, selling an estimated $93.4M.
  • Deerfield Management's ten largest holdings make up 28% of its $2.85B portfolio in Q2 2018.
  • Deerfield Management opened 16 new positions and closed 17 in Q2 2018.
  • Deerfield Management's portfolio value fell 1.3% quarter-over-quarter to $2.85B.

Based on Deerfield Management's 13F filing for Q2 2018, filed 14 Aug 2018.